Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferiprone Safety and Antiretroviral Activity in HIV
NCT02191657Phase 1Completed
- Sponsor
- ApoPharma Inc.
- Start
- Nov 2006
- Primary completion
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of deferiprone in human immunodeficiency virus infection (HIV) (3 cohorts), sponsored by ApoPharma Inc. Primary endpoints: Occurrence of adverse events at 9 weeks, Measurement of viral load at 9 weeks and 2 more. Started Nov 2006; status: completed.
02
Drugs
deferiprone
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02191657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02191657.